Show simple item record

dc.contributor.authorTsoukalas, N
dc.contributor.authorTsapakidis, K
dc.contributor.authorGalanopoulos, M
dc.contributor.authorKaramitrousis, E
dc.contributor.authorKamposioras, Konstantinos
dc.contributor.authorTolia, M
dc.date.accessioned2020-08-10T08:09:18Z
dc.date.available2020-08-10T08:09:18Z
dc.date.issued2020en
dc.identifier.citationTsoukalas N, Tsapakidis K, Galanopoulos M, Karamitrousis E, Kamposioras K, Tolia M. Real world data regarding the management of cancer-associated thrombosis. Curr Opin Oncol. 2020;32(4):289-94.en
dc.identifier.pmid32541315en
dc.identifier.doi10.1097/cco.0000000000000646en
dc.identifier.urihttp://hdl.handle.net/10541/623080
dc.description.abstractPurpose of review: Patients with cancer are at high risk for thrombotic events, mainly deep vein thrombosis and pulmonary embolism. Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the current treatment options for cancer-associated thrombosis (CAT). We assessed real world data (RWD) regarding treatment patterns of CAT from 1 September 2018 to 31 January 2020. Recent findings: RWD showed that LMWHs were the most common initial anticoagulation treatment for CAT. Based on these data DOACs had a lower risk of recurrent venous thromboembolism compared with LMWHs and warfarin. However, the selection bias and the small number of patients in these studies might explain this difference and these limitations should be taken into consideration. Moreover, there was no statistical difference regarding adverse events during anticoagulant treatment between LMWHs and DOACs with the limitations of RWD. As far as the duration of the treatment is concerned, the adherence ranged from 100% to 67.3% at 6 months. Summary: The current review of RWD illustrates that LMWHs and DOACs are used for the treatment of CAT. LMWHs are most commonly used for the initial management of CAT. Data regarding recurrence of CAT, adverse events, compliance and duration of anticoagulant treatment should be analyzed with caution as RWD are observational studies with many limitations. Further research is needed to elucidate the best algorithm for the management of CAT.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/cco.0000000000000646en
dc.titleReal world data regarding the management of cancer-associated thrombosisen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, 401 Military Hospital of Athens, Athens.en
dc.identifier.journalCurrent Opinion in Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record